MYX — Mayne Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- AU$206.36m
- AU$169.56m
- AU$387.35m
Annual cashflow statement for Mayne Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -32.3 | -38.9 | -2.65 | -33.2 | -11.8 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.21 | -42.7 | -15.3 | 17.5 | 13.9 |
| Capital Expenditures | -11.9 | -220 | -20.9 | -29 | -3.32 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -16.7 | 693 | 74.3 | -39.1 | 13.3 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -28.5 | 473 | 53.4 | -68.1 | 10 |
| Financing Cash Flow Items | -9.41 | -4.81 | 5.75 | 3.29 | 1.75 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 27.6 | -432 | -19.9 | -0.556 | -1.48 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.31 | -4.06 | 17.5 | -50.2 | 20.2 |